Patent US5049372A successfully refreshed from Google Patents.
US5049372A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Anticancer activities in a host by increasing blood and plasma adenosine 5'-triphosphate (ATP) levels
Assignee: Individual
•
Filing: 1988-07-25
•
Granted: 1991-09-17
•
Expires: 2008-07-25
Abstract
Abstract Growth of tumor cells in a host is arrested by the generation of elevated blood and plasma levels of adenosine 5'-triphosphate in said host. These elevated levels can be achieved, for instance, by administering adenosine 5'-monophosphate, adenosine 5'-triphosphate, pharmaceutically acceptable salts thereof, or chelates thereof, or radio-nuclides thereof. Weight loss caused by cancer cachexia is substantially inhibited.
Inventors
- 👤 Eliezer Rapaport
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 13:27
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61P; A61P35/00; C; C07; C07H; C07H19/00; C07H19/02; C07H19/04; C07H19/16; C07H19/20
Claims Analysis
Total Claims: 49
Claim 1
Independent Claim
65 words
A process for selectively arresting the growth of tumor cells in a host which comprises administering to a host having tumor cells adenosine 5'-monophosphate, or pharmaceutically acceptable salts thereof, or chelates thereof or liposomes thereof, or radio-nuclides thereof in an amount sufficient to increase the blood and plasma levels of adenosine 5'-triphosphate in said host sufficiently to thereby arrest the growth of said tumor cells.
Claim 2
Dependent Claim
65 words
A process for selectively arresting the growth of tumor cells in a host which comprises administering to a host having tumor cells adenosine 5'-monophosphate, or pharmaceutically acceptable salts thereof, or chelates thereof or liposomes thereof, or radio-nuclides thereof in an amount sufficient to increase the blood and plasma levels of adenosine 5'-triphosphate in said host sufficiently to thereby arrest the growth of said tumor cells.
Claim 3
Dependent Claim
29 words
The process of claim 1 wherein said amount is a low dose of about 0.1 to about 1,000 mg/kg of body weight and said administering is oral or topical.
Claim 4
Dependent Claim
25 words
The process of claim 1 wherein said amount is a low dose of about 1-100 mg/kg of body weight and said administering is by injection.
Claim 5
Dependent Claim
26 words
The process of claim 1 wherein said delivery is accomplished by infusion at a rate of 0.001-15 mg/kg of body weight of said host per minute.
Claim 6
Dependent Claim
10 words
The process of claim 1 wherein adenosine 5'-monophosphate is administered.
Claim 7
Dependent Claim
14 words
The process according to claim 1 wherein said tumor cells are human tumor cells.
Claim 8
Dependent Claim
15 words
The process according to claim 6 wherein said human tumor cells are a solid tumor.
Claim 9
Dependent Claim
83 words
A process for selectively arresting the growth of tumor cells in a host and while substantially inhibiting weight loss caused by cancer cachexia in said host which comprises treating a host afflicted with a tumor to the extent that host tissues or organ functions are adversely effected to increase the blood and plasma levels of adenosine 5'-triphosphate in said host to a level sufficient to thereby arrest the growth of said tumor cells and while substantially inhibiting weight loss caused by cancer cachexia.
Claim 10
Dependent Claim
83 words
A process for selectively arresting the growth of tumor cells in a host and while substantially inhibiting weight loss caused by cancer cachexia in said host which comprises treating a host afflicted with a tumor to the extent that host tissues or organ functions are adversely effected to increase the blood and plasma levels of adenosine 5'-triphosphate in said host to a level sufficient to thereby arrest the growth of said tumor cells and while substantially inhibiting weight loss caused by cancer cachexia.
Claim 11
Dependent Claim
36 words
The process of claim 8 wherein said treating is with at least one compound selected from the group of adenosine 5'-monophosphate, adenosine 5'-diphosphate, adenosine 5'-triphosphate, pharmaceutically acceptable salts thereof, chelates thereof, liposomes thereof and radio-nuclides thereof.
Claim 12
Dependent Claim
25 words
The process of claim 8 wherein said treating is with adenosine 5'-monophosphate or pharmaceutically acceptable salts thereof, or chelates thereof, or liposomes thereof radio-nuclides thereof.
Claim 13
Dependent Claim
12 words
The process of claim 8 wherein said treating is with adenosine 5'-monophosphate.
Claim 14
Dependent Claim
25 words
The process of claim 8 wherein said treating is with adenosine 5'-triphosphate, or pharmaceutically acceptable salts thereof, or chelates thereof, or liposomes thereof radio-nuclides thereof.
Claim 15
Dependent Claim
12 words
The process of claim 8 wherein said treating is with adenosine 5'-triphosphate.
Claim 16
Dependent Claim
29 words
The process of claim 8 wherein said amount is a low dose of about 1 to about 1,000 mg/kg of body weight and said administering is oral or topical.
Claim 17
Dependent Claim
25 words
The process of claim 8 wherein said amount is a low dose of about 1-1,000 mg/kg of body weight and said administering is by injection.
Claim 18
Dependent Claim
26 words
The process of claim 8 wherein said delivering is accomplished by infusion at a rate of 0.001-15 mg/kg of body weight of said host per minute.
Claim 19
Dependent Claim
12 words
The process of claim 8 wherein said host is a human host.
Claim 20
Dependent Claim
35 words
A process for treatment of tumors in a host which comprises treating a tumor-bearing host to increase the blood and plasma levels of adenosine 5'-triphosphate in said host to a level sufficient for said treatment.
Claim 21
Dependent Claim
35 words
A process for treatment of tumors in a host which comprises treating a tumor-bearing host to increase the blood and plasma levels of adenosine 5'-triphosphate in said host to a level sufficient for said treatment.
Claim 22
Dependent Claim
25 words
The process of claim 18 wherein said treating is with adenosine 5'-monophosphate or pharmaceutically acceptable salts thereof, or chelates thereof liposomes thereof, or radio-nuclides thereof.
Claim 23
Dependent Claim
29 words
The process of claim 19 wherein said amount is a low dose of about 1 to about 1000 mg/kg of body weight and said administering is oral or topical.
Claim 24
Dependent Claim
29 words
The process of claim 18 wherein said amount is a low dose of about 1 to about 1000 mg/kg of body weight and said administering is oral or topical.
Claim 25
Dependent Claim
25 words
The process of claim 18 wherein said amount is a low dose of about 1-100 mg/kg of body weight and said administering is by injection.
Claim 26
Dependent Claim
25 words
The process of claim 19 wherein said amount is a low dose of about 1-100 mg/kg of body weight and said administering is by injection.
Claim 27
Dependent Claim
10 words
The process of claim 18 wherein adenosine 5'-monophosphate is administered.
Claim 28
Dependent Claim
12 words
The process of claim 18 wherein said tumor is a human tumor.
Claim 29
Dependent Claim
12 words
The process of claim 18 wherein said host is a human host.
Claim 30
Dependent Claim
26 words
The process of claim 18 wherein said administering is accomplished by infusion of a rate of 0.001-15 mg/kg of body weight of said host per minute.
Claim 31
Dependent Claim
26 words
The process of claim 19 wherein said administering is accomplished by infusion at a rate of 0.001-15 mg/kg of body weight of said host per minute.
Claim 32
Dependent Claim
58 words
A process for increasing the blood and plasma levels of adenosine 5'-triphosphate in a host which comprises administering at least one compound selected from the group of adenosine 5'-monophosphate, adenosine 5'-diphosphate, adenosine 5'-triphosphate, pharmaceutically acceptable salts thereof, chelates thereof liposomes thereof, and radio-nuclides thereof to said host in an amount sufficient to increase said blood and plasma levels.
Claim 33
Dependent Claim
58 words
A process for increasing the blood and plasma levels of adenosine 5'-triphosphate in a host which comprises administering at least one compound selected from the group of adenosine 5'-monophosphate, adenosine 5'-diphosphate, adenosine 5'-triphosphate, pharmaceutically acceptable salts thereof, chelates thereof liposomes thereof, and radio-nuclides thereof to said host in an amount sufficient to increase said blood and plasma levels.
Claim 34
Dependent Claim
29 words
The process of claim 29 wherein said amount is a low dose of about 1 to about 100 mg/kg of body weight and said administering is oral or topical.
Claim 35
Dependent Claim
25 words
The process of claim 29 wherein said amount is a low dose of about 1-100 mg/kg of body weight and said administering is by injection.
Claim 36
Dependent Claim
26 words
The process of claim 29 wherein said administering is accomplished by infusion at a rate of 0.001-15 mg/kg of body weight of said host per minute.
Claim 37
Dependent Claim
13 words
The process of claim 29 wherein adenosine 5'-monophosphate or adenosine 5'-triphosphate is administered.
Claim 38
Dependent Claim
28 words
The process of claim 29 wherein at least one compound from the group of adenosine 5'-triphosphate pharmaceutically acceptable salts thereof, chelates thereof, liposomes thereof and radio-nuclides is administered.
Claim 39
Dependent Claim
10 words
The process of claim 29 wherein adenosine 5'-triphosphate is administered.
Claim 40
Dependent Claim
13 words
The process according to claim 29 wherein said host is a human host.
Claim 41
Dependent Claim
28 words
The process of claim 29 wherein at least one compound from the group of adenosine 5'-monophosphate, pharmaceutically acceptable salts thereof, chelates thereof, liposomes thereof and radio-nuclides is administered.
Claim 42
Dependent Claim
10 words
The process of claim 29 wherein adenosine 5'-monophosphate is administered.
Claim 43
Dependent Claim
26 words
The process of claim 29 wherein said delivering is accomplished by infusion at a rate of 0.001-1.5 mg/kg of body weight of said host per minute.
Claim 44
Dependent Claim
10 words
The process of claim 29 wherein the administering is oral.
Claim 45
Dependent Claim
22 words
The process of claim 40 wherein said amount is a low dose of about 1 to about 10 mg/kg of body weight.
Claim 46
Dependent Claim
10 words
The process of claim 29 wherein the administering is topical.
Claim 47
Dependent Claim
22 words
The process of claim 42 wherein said amount is a low dose of about 1 to about 10 mg/kg of body weight.
Claim 48
Dependent Claim
11 words
The process of claim 29 wherein the administering is by injection.
Claim 49
Dependent Claim
21 words
The process of claim 44 wherein said amount is a low dose of about 1 to 10 mg/kg of body weight.
References Cited (Backward Citations)
US4141972A
Cited
JPS5253897A
Cited
JPS5540635A
Cited
JPS5634697A
Cited
EP0100022A1
Cited
US4880918A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-09-16 | 1995-03-18 | 1995-09-17 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-09-16 | 1999-03-18 | 1999-09-17 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-09-16 | 2003-03-18 | 2003-09-17 | $7700.00 | Window Closed / Lapsed |